Guess AF listened to Norbert Bischofberger too :) The virologic failure rate difference was higher in ECHO trial (11.0% vs 4.4%) than in THRIVE (7.1% vs 5.3%), and there's no explanation for this either.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.